Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biofrontera Inc.
  6. Summary
    BFRI   US09077D1000

BIOFRONTERA INC.

(BFRI)
  Report
Real-time Estimate Cboe BZX  -  12:45:51 2023-02-02 pm EST
0.8690 USD   +0.93%
01/31Benchmark Adjusts Price Target on Biofrontera to $7 From $11, Reiterates Buy Rating
MT
01/09Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial
MT
01/09Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/27/2023 01/30/2023 01/31/2023 02/01/2023 02/02/2023 Date
0.9182(c) 0.9(c) 0.8498(c) 0.861(c) 0.8781 Last
64 561 131 362 463 969 140 924 68 500 Volume
-0.69% -1.98% -5.58% +1.32% +1.99% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 28,9 M - -
Net income 2022 -0,93 M - -
Net Debt 2022 - - -
P/E ratio 2022 -19,1x
Yield 2022 -
Sales 2023 41,5 M - -
Net income 2023 -13,2 M - -
Net Debt 2023 - - -
P/E ratio 2023 -1,79x
Yield 2023 -
Capitalization 23,0 M 23,0 M -
Capi. / Sales 2022 0,80x
Capi. / Sales 2023 0,55x
Nbr of Employees 69
Free-Float 57,6%
More Financials
Company
Biofrontera Inc. is a biopharmaceutical company. The Company is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. It also markets a topical antibiotic for... 
Sector
Pharmaceuticals
Calendar
04/07Earnings Release
More about the company
Ratings of Biofrontera Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about BIOFRONTERA INC.
01/31Benchmark Adjusts Price Target on Biofrontera to $7 From $11, Reiterates Buy Rating
MT
01/09Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial
MT
01/09Biofrontera Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Study Evalua..
CI
01/09Biofrontera Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended D..
CI
2022Biofrontera Inc. Announces Voting Results from 2022 Annual Meeting of Stockholders
AQ
2022Biofrontera Inc. : Change in Directors or Principal Officers, Submission of Matters to a V..
AQ
2022Biofrontera Inc. to Participate in Benchmark's 11th Annual Discovery One-on-One Investo..
GL
2022Biofrontera inc. to participate in renmark's virtual non-deal roadshow series on wednes..
GL
2022Biofrontera inc. to participate in renmark's virtual non-deal roadshow series on wednes..
AQ
2022Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz«-PDT for the Treatment o..
GL
2022Biofrontera Inc. to Launch Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Trea..
CI
2022Transcript : Biofrontera Inc., Nine Months 2022 Earnings Call, Nov 14, 2022
CI
2022BIOFRONTERA INC. Management's Discussion and Analysis of Financial Condition and Resul..
AQ
2022Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended S..
CI
2022Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $4.3M, vs. Street Est of $4.3M
MT
More news
News in other languages on BIOFRONTERA INC.
01/09Biofrontera administre la dose au premier patient de l'essai clinique de phase 3 sur la..
01/09Biofrontera Inc. annonce l'administration de la dose au premier patient de l'étude clin..
01/09Biofrontera Inc. fournit des prévisions de revenus pour le quatrième trimestre et l'ann..
2022Biofrontera Inc. va lancer une étude clinique de phase 3 évaluant l'Ameluz(R)-PDT pour ..
2022Biofrontera Inc. déclare ses résultats pour le troisième trimestre et les neuf mois ter..
More news
Analyst Recommendations on BIOFRONTERA INC.
More recommendations
Chart BIOFRONTERA INC.
Duration : Period :
Biofrontera Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOFRONTERA INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,86 $
Average target price 13,50 $
Spread / Average Target 1 468%
EPS Revisions
Managers and Directors
Erica L. Monaco Chief Executive, Operating & Financial Officer
Fred Leffler Chief Financial Officer
Hermann LŘbbert Executive Chairman
Armin Ollig Vice President-Information Technology
Daniel Hakansson General Counsel & Head-Compliance
Sector and Competitors
1st jan.Capi. (M$)
BIOFRONTERA INC.-6.07%23
JOHNSON & JOHNSON-6.64%431 181
ELI LILLY AND COMPANY-5.93%325 502
NOVO NORDISK A/S0.47%312 239
MERCK & CO., INC.-3.58%271 237
ROCHE HOLDING AG-3.82%269 501